Ionis Pharmaceuticals, Inc. (IONS) slumps 19.5% on trial miss
Ionis Pharmaceuticals, Inc. (IONS) slumps after hours after a Phase 3 CARDIO-TTRansform trial miss for eplontersen, also known as WAINUA. The setback dents a key expansion story in ATTR-CM and raises questions about future royalty growth, even as the company remains commercially diversified.
Ionis Pharmaceuticals, Inc. (IONS) slumps 19.5% in after-hours trading after AstraZeneca and Ionis said the Phase 3 CARDIO-TTRansform trial for eplontersen, or WAINUA, missed its primary endpoint in ATTR-CM. The failed expansion readout removes a major growth catalyst and forces investors to reprice the stock around a weaker long-term revenue outlook, even though Ionis still has a diversified commercial and pipeline portfolio.
Ionis Pharmaceuticals, Inc. (IONS) slumps in after-hours trading, with the stock falling to $68 from a prior regular-session close of $84.46, a drop of 19.49%. The selloff is significant because it hits a biotech name that had been trading near its 52-week high of $86.74 and had enjoyed strong analyst support and positive sentiment heading into the move.
Key Takeaways
IONS is down 19.49% in extended-hours trading, falling to $68 from $84.46.
The clearest catalyst is the Phase 3 CARDIO-TTRansform trial miss for eplontersen, also marketed as WAINUA, in transthyretin-mediated amyloid cardiomyopathy.
That study failed its primary endpoint of reducing cardiovascular mortality and recurrent cardiovascular events through Week 140 versus placebo.
WAINUA matters financially because Ionis booked $11M in royalty revenue from $51M in global WAINUA sales in Q1 2026.
For investors, the drop looks less like a balance-sheet problem and more like a pipeline repricing tied to a lost expansion opportunity.
The most likely reason for the sharp move is now clear. Ionis and AstraZeneca reported that the Phase 3 CARDIO-TTRansform trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, missed its primary endpoint. Specifically, the study failed to show a benefit on the composite of cardiovascular mortality and recurrent cardiovascular events through Week 140 compared with placebo.
That matters because WAINUA was not just another pipeline shot. It was a late-stage program tied to a large commercial market and a major strategic partner in AstraZeneca(AZN). When a late-stage cardiovascular expansion fails, the market usually cuts projected peak sales fast. In biotech, that repricing can be brutal, and this move fits that pattern.
The reaction also lines up with peer trading. Reports on July 9 said Pfizer(PFE), Alnylam(ALNY), and BridgeBio(BBIO), all active in ATTR-CM, moved higher after the AstraZeneca-Ionis setback. That is classic market behavior. A failed rival trial does not just hurt the sponsor. It can strengthen the hand of competitors at the same time.
Why the WAINUA Trial Miss Matters to Ionis Financially
Ionis is more diversified than a one-asset biotech, but WAINUA still matters. In Q1 2026, WAINUA generated $51M in global sales and produced $11M in royalty revenue for Ionis. That is meaningful because Ionis runs a business model built on commercial products, royalties, milestones, and partnered programs. A setback in one of those royalty-bearing assets hits both near-term confidence and long-term valuation.
Just as important, the failed study was aimed at ATTR-CM, a much broader and more commercially attractive market than narrower rare-disease use cases. In plain English, the market was valuing not only current WAINUA sales but also the chance that the drug could expand into a bigger indication. When that expansion case breaks, investors do not mark down the asset a little. They usually take a machete to the future revenue curve.
Ionis also has meaningful partner economics tied to the program. Company materials state that after Dec. 31, 2025, AstraZeneca is responsible for 75% of development costs in the U.S. and 87.5% in some later-stage contexts. That structure lowers Ionis' spending burden, but it also reinforces how important partnered outcomes are to the stock. If the partner asset stumbles, Ionis still feels it.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How Ionis Pharmaceuticals, Inc.'s Fundamentals Look After the Drop
The selloff does not erase the broader business overnight. Ionis remains a commercial-stage biotech with approved products including TRYNGOLZA, DAWNZERA, WAINUA, and SPINRAZA. It also still carries a market cap of about $13.96B based on the data before the after-hours move, which tells you this is not a tiny speculative biotech living on one binary event.
Recent earnings execution had also been solid. Ionis beat EPS estimates in each of the last seven reported quarters. In the most recent quarter reported on April 29, 2026, it posted EPS of -$0.30 versus an estimate of -$0.77, a 61% surprise. That history matters because it shows the current drop is not tied to a fresh earnings miss or a sudden collapse in operating discipline.
Analyst sentiment had been constructive as well. In late June, H.C. Wainwright raised its price target to $130, while Goldman Sachs raised its target to $75. The broader analyst consensus stood at Buy, with a median target of $110 and a consensus target of $107.22. Meanwhile, quantified news sentiment was strongly positive, with a 7-day score of 0.963. That backdrop helps explain why the stock is reacting so hard now. Expectations were not washed out. They were elevated.
This kind of decline usually forces a reset in how investors value Ionis. The company still has a broad antisense platform and multiple commercial and pipeline assets. It also has recent positives, including FDA acceptance of the zilganersen NDA with Priority Review and a PDUFA date of Sept. 22, 2026. So the story is bruised, not broken.
Still, the market is sending a direct message. Late-stage failures in big indications carry more weight than routine quarterly beats. For short-term traders, that often means volatility stays high as the stock digests the loss of a major growth leg. For longer-term investors, the real issue is whether the remaining pipeline and commercial portfolio can support the valuation without a successful ATTR-CM expansion for eplontersen.
There is also a competitive angle. With Pfizer, Alnylam, and BridgeBio shares rising on the same news, the market is already reallocating value toward surviving players in ATTR-CM. That does not help Ionis. In biotech, capital rarely sits still when one lane clears for rivals.
Ionis Pharmaceuticals, Inc. (IONS) is falling sharply because the Phase 3 CARDIO-TTRansform trial for eplontersen missed its primary endpoint in ATTR-CM, damaging a key expansion narrative for WAINUA. Since this is an after-hours move, the regular session will show whether the full 19.49% drop holds, but the early verdict from the market is straightforward: a meaningful late-stage value driver just took a hard hit.
IONS is falling because the Phase 3 CARDIO-TTRansform trial for eplontersen (WAINUA) missed its primary endpoint in ATTR-CM. That setback weakens a key growth thesis and triggered a sharp after-hours selloff.
+Should I buy IONS stock now?
The article suggests caution, not urgency. Ionis still has multiple approved products and a strong pipeline, but the stock now faces a valuation reset after losing a major late-stage catalyst.
+What trial caused Ionis Pharmaceuticals to slump?
The selloff was driven by the Phase 3 CARDIO-TTRansform trial of eplontersen, also marketed as WAINUA. The study failed to reduce cardiovascular mortality and recurrent cardiovascular events versus placebo.
+Does this drop change Ionis's long-term outlook?
It hurts the long-term growth story, but it does not break the company. Ionis still has commercial products, royalty revenue, and other pipeline catalysts, so the business remains intact even as expectations reset.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on IONS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
